Investor Relations

Featured Events

Johnson & Johnson Third Quarter 2014 Earnings Meeting and Webcast
October 14, 2014
8:30 AM ET

Stock Symbol JNJ
Current Price $107.86
Change $+0.38
Day High $108.73
Day Low $107.62
Volume 8,395,100
Trades 40,110
11/21/2014 4:04 PM
Minimum 20 mins delay.

Stock Transfer Agent
outside the U.S. and Canada

Investing in Johnson & Johnson.

Johnson & Johnson has been a part of people's lives for 128 years and a valuable part of their investments for approximately 70 years. Founded in 1886, we listed our shares on the New York Stock Exchange for public investors in 1944.

During our history, we have built the most comprehensive base of health care businesses in the world, generating approximately 70 percent of our revenues from No. 1 or No. 2 global leadership positions in our respective markets.

Our consistent performance has enabled us to deliver an exceptional track record of growth that few, if any, companies can claim: 30 consecutive years of adjusted earnings increases; and 52 consecutive years of dividend increases. Over the last 10 years, Johnson & Johnson stock generated a 8.9 percent total return for investors compared to a 7.4 percent total return for the S&P 500.(1)

E-Delivery of Annual Meeting and Proxy Materials

Johnson & Johnson is dedicated to improving the health and well-being of people everywhere. To fulfill this goal, we must protect the environments in which we work and live. A healthy planet and a healthy community go hand in hand. With this in mind, we now offer electronic versions of all of our company publications like the Annual Report.

Click here for the Johnson & Johnson 2013 Annual Report
Click here for the Johnson & Johnson 2014 Proxy Statement
Click here for the Johnson & Johnson 2013 Digital Annual Report

You can do your part as well. By reducing the amount of printed shareholder materials you receive, you can help protect the environment while quickly receiving important shareholder documents. In addition, reducing the printing and mailing costs associated with more traditional delivery methods allows us to control expenses in the interest of delivering more value for all our shareholders.

Registered Johnson & Johnson shareholders can sign up for electronic delivery of our reports and publications. Please go to or contact our transfer agent, Computershare, at 1-800-328-9033.

Beneficial (owned through a broker/bank) Johnson & Johnson shareholders can register for on-line delivery of materials by clicking here and following the easy directions to your account.

Investor News

November 19, 2014
Janssen Submits New Drug Application to U.S. FDA for Three-Month Paliperidone Palmitate

November 18, 2014
Real-World Data Presented at the American Heart Association (AHA) Scientific Sessions Underscore Hospitalization and Outpatient Cost-Savings for XARELTO® Compared to Standard of Care

November 13, 2014
U.S. FDA Approves Supplemental New Drug Applications for Once-Monthly Long-Acting Therapy INVEGA® SUSTENNA® (paliperidone palmitate) for the Treatment of Schizoaffective Disorder

Investor Communications

October 14, 2014 at 8:30 AM ET
Johnson & Johnson Third Quarter 2014 Earnings Meeting and Webcast

Financial Quick Links

Johnson & Johnson Reports 2014 Third-Quarter Results

Sales of Key Products/Franchises Q3 2014

Reconciliation of Non-GAAP Financial Measures Q3 2014

5 Year Financial Review

1. Data source - Bloomberg